Clinical trial

A Clinical Study With Adalimumab Biosimilar

NCT06291948

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-08-01

PhasePHASE1

Study timeline

Study start (actual)2022-08-01Date precision: day

Registry last updated2024-03-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Pharmacokineticsunresolved

Safety Issuesunresolved

Interventions

Humira® (adalimumab) AC Pen [Reference Product]BIOLOGICAL

Adalimumab Richmond [Test Product]BIOLOGICAL

Sponsors & collaborators

Laboratorios Richmond S.A.C.I.F.lead sponsor

FP Clinical Pharma S.R.L.collaborator

Custom Biologicscollaborator

Mapped research locations

Buenos AiresArgentina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06291948 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.